Cargando…
What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review
BACKGROUND: Psilocybin is a predominant agonist of 5HT(1A) and 5HT(2A/C) receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedeli...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055489/ https://www.ncbi.nlm.nih.gov/pubmed/33884324 http://dx.doi.org/10.1097/j.pbj.0000000000000128 |